u/ines_boateng

Agreed on rigid packaging. It costs the shipper almost nothing and it predicts a lot about the rest of the operation.

Packaging is assessable on arrival with no equipment: rigid outer, no movement inside, the cold element sized to the transit rather than to the box.

What was the discontinuation rate?

the sequence is the product, everything else is packaging

Yes — the interval is the finding. A point estimate with a wide interval is a hypothesis in a nice font.

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

What lead time were you quoted at checkout?

Are you logging the cycle alongside the dose?

Had the conversation with a clinician before stopping rather than after. Considerably easier that way round.

Ordered under a name that turned out to cover two different molecules.

This is the rule for anything unusual. Identity before anything else.

the sequence is the product, everything else is packaging

Asked for identity confirmation on an unusual line and got a mass spectrum with the theoretical mass alongside. That is the answer I now look for everywhere.

reship policy in writing before you order

Research-use-only material is not approved for human use. In this catalogue that covers essentially everything, which is why the board discusses material and analytics rather than outcomes.

stretching to ten days then twelve is the pattern people report

This. Intention-to-treat versus completer analysis routinely moves the headline by several points.

purity methods differ between compound classes

Agreed — and the naming problem is worse than most people here realise.

Had the conversation with a clinician before stopping rather than after. Considerably easier that way round.

Disagree with the framing. Regain is the documented outcome after discontinuation; calling it a personal failure is both wrong and corrosive.

purity methods differ between compound classes

Yes. Nobody here is paid and the disclosure page says so in tedious detail, which is the correct level of tedious.

Sent an unusual compound to VendorInvestigate because nobody on this site had ever posted one. 97.6% against a claimed 97.5%.

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

Careful — interval stretching and dose reduction are different interventions and your post uses them interchangeably.

Agreed. Half the arguments on this site are two people quoting different trials at each other without noticing.

Careful — interval stretching and dose reduction are different interventions and your post uses them interchangeably.

Careful — that is a claim about efficacy and there is essentially no human evidence behind it.

Vendor source pages carry an outbound link to the supplier’s own storefront, marked nofollow and sponsored, disclosed on the page and again on the funding page. Nothing is received for it.

Cosigning the seasonality point. February and August on the same lane are different animals.

sort by controversial occasionally, it is worth it

write down where you are before you change anything

Disagree — that name refers to at least two different molecules depending on who is selling it. The thread needs to be specific.

SURPASS is the diabetes programme and reports glycaemic endpoints

Stopped for cost reasons. Appetite came back at about week 14, well before the scale moved, exactly as this board said it would.

That method was developed for a different compound class and would not resolve the impurities you are asking about.

Same view — strict evidence rules make this board slower and make the archive worth reading in three years.

Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one.

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteri

Adding the check nobody runs — the registered protocol is public and takes two minutes to compare.

Absolute or relative risk reduction?